Form 990 for tax year 2024

Totals

Total revenue

$64,992,602

Total expenses

$113,224,542

Contributions and grants received

$28,432,107

Grants paid

$0

Program service revenue

$5,439,790

Investment income

$2,226,750

Other revenue

$28,893,955

Total assets, end of year

$283,067,991

Total liabilities, end of year

$303,721,065

Net assets or fund balances, end of year

-$20,653,074

Program services expenses (Part IX)

$87,342,285

Management and general expenses

$25,882,257

Fundraising expenses

$0

Program service expenses (Part III)

$87,342,285

Program services were 77.1% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2024

• GENERIC DRUG DISTRIBUTIONDEVELOP AN OPEN AND GROWING NETWORK OF HOSPITALS TO EXPAND THE REACH OF CIVICA'S MISSION AND ITS BENEFITS TO BOTH MEMBERS AND NON-MEMBERS. ALLEVIATE SHORTAGES OF ESSENTIAL DRUG PRODUCTS AND STABILIZE PRICING BY SECURING AVAILABILITY FROM EXISTING MANUFACTURERS FOR THE BENEFIT OF PATIENTS SERVED BY THESE MEMBERS AND NON-MEMBER CUSTOMERS. CIVICA'S MAJOR ACCOMPLISHMENTS TO DATE INCLUDE THE FOLLOWING:(1) CONTINUED CUSTOMER GROWTH WITH 85 MILLION PATIENTS SERVED TO DATE. NEW CUSTOMERS ENROLLED INCLUDE NATIONWIDE NON-MEMBER 340B HOSPITALS THAT SERVE A DISPROPORTIONATE POPULATION OF HIGH-NEED PATIENTS, VETERANS AFFAIRS HOSPITALS, AND THE DEPARTMENT OF DEFENSE. (2) CONTINUED LAUNCH OF ESSENTIAL MEDICINES DEEMED IN SHORT SUPPLY PER THE FDA OR ASHP DRUG SHORTAGES LISTS.(3) ESTABLISHED AND MAINTAINED APPROXIMATELY 6 MONTHS OF FINISHED GOODS INVENTORY TO BUFFER ANY SUPPLY CHAIN SHOCKS TYPICALLY EXPERIENCED IN THE INDUSTRY FOR ESSENTIAL STERILE INJECTABLE MEDICINES. (4) SINGLE TRANSPARENT AFFORDABLE PRICING TO ALL MEMBERS AND NON-MEMBERS REGARDLESS OF MEMBERSHIP STATUS, SIZE OF THE HOSPITAL, VOLUME OF DRUGS PURCHASED FROM CIVICA OR RELATIONSHIP LONGEVITY WITH CIVICA.

  Expenses $36,894,776 · Revenue $31,500,392

• FILL - FINISH FACILITYTHE COVID-19 PANDEMIC, WHICH RESULTED IN A SPIKE IN DEMAND FOR MEDICATIONS IN HOSPITALS MANAGING SIGNIFICANT PATIENT SURGES, BROUGHT TO LIGHT THE DEPENDENCE OF THE UNITED STATES ON FOREIGN MANUFACTURERS OF GENERIC, ESSENTIAL, LIFE-SAVING MEDICATIONS; ESPECIALLY STERILE INJECTABLES. IN AN EFFORT TO ON-SHORE END-TO-END MANUFACTURING OF SUCH STERILE INJECTABLES, AND AS A NATIONAL SECURITY MEASURE, BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY ("BARDA"), A U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ("HHS") GOVERNMENT OFFICE RESPONSIBLE FOR THE PROCUREMENT AND DEVELOPMENT OF MEDICAL COUNTERMEASURES, PRINCIPALLY AGAINST BIOTERRORISM, INCLUDING CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR THREATS, AS WELL AS PANDEMIC INFLUENZA AND EMERGING DISEASES, AWARDED CONTRACT NO. 75A50120C00092 ("PRIME CONTRACT") TO PHLOW CORP., ("PHLOW") TO CREATE END-TO-END MANUFACTURING IN THE UNITED STATES. PHLOW IS A DELAWARE PUBLIC BENEFIT CORPORATION ENGAGED IN THE BUSINESS OF THE RESEARCH, DEVELOPMENT, AND COMMERCIALIZATION OF PHARMACEUTICAL PRODUCTS. PHLOW SUBCONTRACTED CERTAIN OF ITS OBLIGATIONS UNDER THE PRIME CONTRACT TO CIVICA WHEREBY CIVICA WILL QUALIFY, DESIGN, BUILD, EQUIP, OPERATE, AND OWN A 120,000 SQUARE FOOT, TWO-STORY, CGMP COMPLIANT ASEPTIC FILL-FINISH FACILITY ("FILL-FINISH FACILITY"), TO BE FUNDED, AT LEAST PARTIALLY, WITH $100,000,000 PROVIDED BY BARDA. THE FILL-FINISH FACILITY WILL BE CAPABLE OF, AMONG OTHER THINGS, PROVIDING AT LEAST 90 MILLION ASEPTIC OR TERMINALLY STERILIZED VIALS AND 50 MILLION PRE-FILLED SYRINGES ANNUALLY. THE FACILITY IS COMPLETE ALONG WITH SUBMISSION OF THE APPLICATION FOR THE APPROVAL OF THE FACILITY. THE FIRST PRODUCTS, AND COMMENCEMENT OF COMMERCIAL PRODUCTION, ARE ANTICIPATED IN 2026. CIVICA INTENDS TO USE THE FILL-FINISH FACILITY TO, AMONG OTHER THINGS, (1) MANUFACTURE STERILE INJECTABLES IN FURTHERANCE OF ITS GENERIC DRUG DISTRIBUTION PROGRAM IDENTIFIED PREVIOUSLY, (2) SUPPORT THE NEEDS OF THE U.S. GOVERNMENT FOR ANY FUTURE PANDEMICS OR SIMILAR EMERGENCIES, (3) PROVIDE SURPLUS MANUFACTURING CAPACITY TO OTHER U.S.-BASED STERILE INJECTABLE MANUFACTURERS WHO SERVE THE NEEDS OF THE COUNTRY FOR SHORTAGE MEDICATIONS, AND (4) PRODUCE LOW-COST INSULIN FOR THE US MARKET TO ALLEVIATE DISTRESS THAT AFFORDABILITY CHALLENGES CAUSE TO PATIENTS.

  Expenses $48,851,416

• OUT-PATIENT SERVICESON OR ABOUT JANUARY 23, 2020, CIVICA ANNOUNCED AN ARRANGEMENT WITH THE BLUE CROSS BLUE SHIELD ASSOCIATION ("BCBSA") AND A NUMBER OF INDEPENDENT BLUE CROSS AND BLUE SHIELD COMPANIES ("BCBSS; WITH BCBSA, THE "BLUES"). THE ARRANGEMENT INVOLVED THE CREATION OF A NEW BUSINESS ENTITY, CIVICASCRIPT, DEDICATED TO LOWERING THE COST OF SELECT OUTPATIENT GENERIC MEDICATIONS IN RESPONSE TO THE IMPACT OF HIGH DRUG COSTS ON THE HEALTH OF AMERICANS AND THE OVERALL AFFORDABILITY OF HEALTH CARE BY DEVELOPING AND MANUFACTURING GENERIC OUTPATIENT MEDICATIONS. IN FURTHERANCE OF THE ARRANGEMENT, ON OR ABOUT JANUARY 27, 2020, CIVICA CAUSED CIVICASCRIPT TO BE ORGANIZED AS A DELAWARE LIMITED LIABILITY COMPANY TO PROMOTE PUBLIC BENEFITS, INCLUDING PROMOTION OF AVAILABILITY OF AFFORDABLE OUTPATIENT GENERIC DRUGS. CIVICASCRIPT, A STATUTORY PUBLIC BENEFIT LLC UNDER DELAWARE LAW , IS TREATED AS A CORPORATION FOR U.S FEDERAL TAX PURPOSES. HOWEVER, CIVICASCRIPT HAS APPLIED FOR TAX-EXEMPT STATUS AS A PUBLIC CHARITY. IF APPROVED, THE EFFECTIVE DATE OF EXEMPTION WOULD BE SEPTEMBER 1, 2023.BASED ON MARKET AND OTHER RESEARCH BY CIVICASCRIPT, AS APPROVED BY ITS BOARD, CIVICASCRIPT IS CURRENTLY IN THE PROCESS OF DEVELOPING GENERIC VERSIONS OF CERTAIN MEDICATIONS. IN ALIGNMENT WITH CIVICASCRIPT'S FOUNDING MISSION, THESE GENERIC MEDICATIONS WILL BE SOLD TO CIVICA-AFFILIATED HOSPITALS, ALL "340B HOSPITALS,", ALL VETERANS AFFAIRS ("VA") HOSPITALS, AND TO RETAILERS.CIVICA, INC. ENTERED INTO A SERVICES AGREEMENT EFFECTIVE SEPTEMBER 1, 2020, WITH CIVICASCRIPT. CIVICA, INC. IS A MEMBER OF CIVICASCRIPT AND A RELATED PARTY. THE PROVISIONS OF THIS AGREEMENT ALLOW FOR CIVICA, INC. TO PROVIDE CIVICASCRIPT WITH ADMINISTRATIVE SUPPORT AND OTHER SERVICES TO ENABLE THE PUBLIC TO REALIZE THE BENEFITS CIVICASCRIPT INTENDS TO PROVIDE. THESE SERVICES INCLUDE EXECUTIVE MANAGEMENT SERVICES, PROFESSIONAL ASSISTANCE, RISK MANAGEMENT, QUALITY & REGULATORY SUPPORT AND OVERSIGHT, FINANCE & ACCOUNTING SERVICES, AND DATA ANALYTICS.

  Expenses $1,210,295 · Revenue $1,210,295

• CIVICA ENTERED INTO A MASTER SERVICE AGREEMENT WITH A US BASED FOR PROFIT PHARMA COMPANY ON APRIL 18, 2024, TO SUPPORT THE GLOBAL SUPPLY OF (FILL AND FINISH) STERILE INJECTABLE MEDICATIONS WHICH WERE ON THE FDA DRUG SHORTAGE LIST, AND FOR WHICH THE PARTNERING COMPANY IS DELAYING LAUNCHES IN MARKETS DUE TO PRODUCTION CAPACITY CONSTRAINTS. PURSUANT TO WORK ORDERS UNDER THIS AGREEMENT, CIVICA IS PRODUCING BOTH PRE-FILLED SYRINGES AND CARTRIDGES FOR ASSEMBLY INTO INJECTION DEVICES. THIS PROGRAM ADVANCES CIVICA'S MISSION TO INCREASE ACCESS TO ESSENTIAL, AFFORDABLE MEDICATIONS BY SUPPORTING A LOW-COST, RELIABLE PRODUCTION OF HIGH-DEMAND, CLINICALLY IMPORTANT TREATMENTS FOR PATIENTS.

  Expenses $385,798 · Revenue $1,623,058

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

• NED MCCOY

  CHIEF EXECUTIVE OFFICER

  Total calculated

  $1,367,160

  From this org

  $790,906

  From related orgs

  $527,270

  Other

  $48,984

  Hours/week

  24 + 16 related

  Schedule J breakdown matched by us

  Base

  $389,446 + $259,630 related

  Bonus

  $401,460 + $267,640 related

  Other

  $0

  Deferred

  $8,280 + $5,520 related

  Nontaxable benefits

  $21,844 + $14,563 related

  Filer's total

  $821,030 + $547,353 related

• DAN LILJENQUIST

  CHAIR

  Total calculated

  $0

  Hours/week

  2 + 3 related

• DENNIS DAHLEN

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• SHELLEY LYFORD

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1 + 2 related

• KATHLEEN SANFORD

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• ANDREA NODA

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• ERIN ASPREC

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• WILLIAM RUTHERFORD

  DIRECTOR (THRU APRIL '24)

  Total calculated

  $0

  Hours/week

  1

• MICHAEL ROWE

  DIRECTOR (THRU AUG. '24)

  Total calculated

  $0

  Hours/week

  1

• DREW HOBBY

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• DAN ROTH

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• HODA ASMAR

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• MAIRIN MANCINO

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• DAVID YODER

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1 + 1 related

• JOHN HACKETT

  DIRECTOR (FROM MAY '24)

  Total calculated

  $0

  Hours/week

  1

• KEVIN SMITH

  DIRECTOR (FROM NOV. '24)

  Total calculated

  $0

  Hours/week

  1

• CHRIS CLAGG

  DIRECTOR (FROM AUG. '24)

  Total calculated

  $0

  Hours/week

  1

• JENNIFER SPALDING

  CHIEF COMM'L OFFICER/GENERAL COUNSEL

  Total calculated

  $929,303

  From this org

  $583,770

  From related orgs

  $314,337

  Other

  $31,196

  Hours/week

  26 + 14 related

  Schedule J breakdown matched by us

  Base

  $273,556 + $147,299 related

  Bonus

  $310,214 + $167,038 related

  Other

  $0

  Deferred

  $8,970 + $4,830 related

  Nontaxable benefits

  $11,577 + $6,234 related

  Filer's total

  $604,317 + $325,401 related

• EAMON FITZMAURICE

  CHIEF FINANCIAL OFFICER

  Total calculated

  $943,747

  From this org

  $534,964

  From related orgs

  $356,643

  Other

  $52,140

  Hours/week

  24 + 16 related

  Schedule J breakdown matched by us

  Base

  $248,614 + $165,743 related

  Bonus

  $286,350 + $190,900 related

  Other

  $0

  Deferred

  $8,280 + $5,520 related

  Nontaxable benefits

  $23,470 + $15,647 related

  Filer's total

  $566,714 + $377,810 related

• DEBBI FORD

  CHIEF COMMUNICATIONS (THRU OCT '24)

  Total calculated

  $858,585

  From this org

  $323,909

  From related orgs

  $485,863

  Other

  $48,813

  Hours/week

  16 + 24 related

  Schedule J breakdown matched by us

  Base

  $133,009 + $199,513 related

  Bonus

  $190,900 + $286,350 related

  Other

  $0

  Deferred

  $5,362 + $8,043 related

  Nontaxable benefits

  $14,405 + $21,608 related

  Filer's total

  $343,676 + $515,514 related

• DONNA GULBINSKI

  CHIEF QUALITY & REG AFFAIRS OFFICER

  Total calculated

  $943,719

  From this org

  $621,572

  From related orgs

  $266,388

  Other

  $55,759

  Hours/week

  28 + 12 related

  Schedule J breakdown matched by us

  Base

  $287,497 + $123,213 related

  Bonus

  $334,075 + $143,175 related

  Other

  $0

  Deferred

  $9,660 + $4,140 related

  Nontaxable benefits

  $30,205 + $12,945 related

  Filer's total

  $661,437 + $283,473 related

• KRISTOPHER WEIDLING

  CHIEF HUMAN RESOURCES

  Total calculated

  $950,643

  From this org

  $796,605

  From related orgs

  $88,512

  Other

  $65,526

  Hours/week

  36 + 4 related

  Schedule J breakdown matched by us

  Base

  $367,080 + $40,787 related

  Bonus

  $429,525 + $47,725 related

  Other

  $0

  Deferred

  $12,342 + $1,371 related

  Nontaxable benefits

  $47,321 + $5,258 related

  Filer's total

  $856,268 + $95,141 related

• JAY BENSON

  CHIEF MFG & SUPPLY CHAIN OFFICER

  Total calculated

  $763,275

  From this org

  $628,559

  From related orgs

  $69,840

  Other

  $64,876

  Hours/week

  36 + 4 related

  Schedule J breakdown matched by us

  Base

  $368,548 + $40,950 related

  Bonus

  $260,011 + $28,890 related

  Other

  $0

  Deferred

  $12,420 + $1,380 related

  Nontaxable benefits

  $46,342 + $5,149 related

  Filer's total

  $687,321 + $76,369 related

• ALLAN COUKELL

  CHIEF GOVT. AFFAIRS/PUBLIC POLICY OFFICER

  Total calculated

  $606,547

  From this org

  $406,420

  From related orgs

  $135,474

  Other

  $64,653

  Hours/week

  30 + 10 related

  Schedule J breakdown matched by us

  Base

  $277,394 + $92,465 related

  Bonus

  $129,026 + $43,009 related

  Other

  $0

  Deferred

  $10,350 + $3,450 related

  Nontaxable benefits

  $38,722 + $12,907 related

  Filer's total

  $455,492 + $151,831 related

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• CIVICA FOUNDATION

  501(C)(3) · FUNDRAISING · DE · controlled entity

  Directly controlled by CIVICA INC

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Provenance

Return type

form_990

Tax year

2024

Filed

15 May 2025

IRS schema version

2024v5.1

Source object

202541359349306264

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.